Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brolucizumab for pigment epithelial detachment secondary to neovascular age-related macular degeneration
ACTRN12621000305820Phase 4Terminated
- Sponsor
- Sydney Retina Clinic and Day Surgery
- Start
- Apr 2021
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of brolucizumab in exudative macular degeneration (2 arms), sponsored by Sydney Retina Clinic and Day Surgery. Primary endpoints: Mean change in pigment epithelial detachment height at week 52 and Proportion of patients with resolution of pigment epithelial detachment at week 52. Started Apr 2021; status: terminated.
02
Drugs
brolucizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on ACTRN12621000305820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000305820.